Published work:
Guidelines
Academic Publications
Collins JT, Noble S, Davies HE, Farewell D, Lester JF, Parry D, Byrne A.
Performance status agreement assessed by the patient and clinician in a rapid access lung cancer service: Can either predict completion of treatment?
Eur J Cancer Care (Engl). 2019 May;28(3)
Hatton MQF, Lawless CA, Faivre-Finn C, Landau D, Lester JF, Fenwick J, Simões R, McCartney E, Boyd KA, Haswell T, Shaw A, Paul J.Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.
BMJ Open. 2019 Jan 29;9(1)
Lester JF, Casbard AC, Al-Taei S, Harrop R, Katona L, Attanoos RL, Tabi Z, Griffiths GO.
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.
Oncoimmunology. 2018 Sep 7;7(12)
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet. 2018 Dec 1;392(10162):2353-2366
Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, Malik ZI, Jones R, Parker CC, Ritchie AWS, Russell JM, Millman R, Matheson D, Amos C, Gilson C, Birtle A, Brock S, Capaldi L, Chakraborti P, Choudhury A, Evans L, Ford D, Gale J, Gibbs S, Gilbert DC, Hughes R, McLaren D, Lester JF, Nikapota A, O'Sullivan J, Parikh O, Peedell C, Protheroe A, Rudman SM, Shaffer R, Sheehan D, Simms M, Srihari N, Strebel R, Sundar S, Tolan S, Tsang D, Varughese M, Wagstaff J, Parmar MKB, James ND; STAMPEDE Investigators.
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Ann Oncol. 2018 May 1;29(5):1235-1248.
Sanganalmath P, Lester JE, Bradshaw AG, Das T, Esler C, Roy AEF, Toy E, Lester JF, Button M, Wilson P, Comins C, Atherton P, Pickles R, Foweraker K, Walker GA, Keni M, Hatton MQ.
Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres.
Clin Oncol (R Coll Radiol). 2018 Mar;30(3):144-150
Talbot T, Dangoor A, Shah R, Naik J, Talbot D, Lester JF, Cipelli R, Hodgson M, Patel A, Summerhayes M, Newsom-Davis T.
The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
Lung Cancer. 2017 Nov;113:115-120
Collins JT, Noble S, Chester J, Davies HE, Evans WD, Farewell D, Lester JF, Parry D, Pettit R, Byrne A.
The value of physical performance measurements alongside assessment of sarcopenia in predicting receipt and completion of planned treatment in non-small cell lung cancer: an observational exploratory study.
Support Care Cancer. 2018 Jan;26(1):119-127
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
N Engl J Med. 2017 Jul 27;377(4):338-351
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Nature. 2017 Apr 26;545(7655):446-451
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium.
Tracking the Evolution of Non-Small-Cell Lung Cancer.
N Engl J Med. 2017 Jun 1;376(22):2109-2121
Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma.
Davies RS, Smith C, Edwards G, Butler R, Parry D, Lester JF.
Lung Cancer Int. 2017;2017:9614938.
Al-Taei S, Salimu J, Spary LK, Clayton A, Lester JF, Tabi Z.
Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: Self-amplifying immunosuppression in cancer.
Oncoimmunology. 2016 Dec 8;6(2):e1268308
Lester JF, Mason MD. Cardiovascular effects of hormone therapy for prostate cancer. Drug Healthcare and Patient Safety. 2015 Jul 7:129-38.
Collins JT, Noble S, Chester J, Davies HE, Evans WD, Lester J, Parry D, Pettit RJ, Byrne A. Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol. BMC Cancer. 2015 Jul 24;15:544
Stevens R, Macbeth F, Toy E, Coles B, Lester JF. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database Syst Rev. 2015 Jan 14;1:CD002143.
Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, Lester J, McPhelim J, Mulatero C, Subramanian S, Thomas A, Thatcher N, Nicolson M. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs. 2015 Aug 75(12):1335-48.
Harrett E, Davies RS, Attanoos R, Lester JF. Lung cancer masquerading as breast cancer with carcinoma en cuirasse. BMJ Case Rep. 2014 Nov 13;2014.
James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MK, Ritchie AW, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015 Jun;67(6):1028-38.
Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol. 2014 Jul 8;12(7):e1001906.
Warren S, Panettieri V, Panakis N, Bates N, Lester JF, Jain P, Landau DB, Nahum AE, Mayles WP, Fenwick JD. Optimizing collimator margins for isotoxically dose-escalated conformal radiation therapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1148-53.
Lester JF, Evans LM, Yousef Z, Penney A, Brown PN, Perks R. A National Audit of Current Cardiac Device Policies from Radiotherapy Centres across the UK. Clin Oncol (R Coll Radiol). 2014 Jan;26(1):45-50
Din OS, Harden SV, Hudson E, Mohammed N, Pemberton LS, Lester JF, Biswas D, Magee L, Tufail A, Carruthers R, Sheikh G, Gilligan D, Hatton MQ. Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: Results from 4 UK centres. Radiother Oncol. 2013 Oct;109(1):8-12
Thomas BM, Smith C, Evans J, Button MR, Kumar S, Palaniappan N, Staffurth J, Tanguay JS, Lester JF. Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. Med Oncol. 2013 Dec;30(4):719.
Pembroke CA, Byrne A, Lester JF, Button M. Persistent unilateral facial pain in lung cancer patients with mediastinal nodal involvement. Lung Cancer. 2013 Oct;82(1):173-5.
Lester JF, Agulnik J, Akerborg O, Chouaid C, De Geer A, Finnern HW, Herder GJ, Lungershausen J, Mitchell PL, Vansteenkiste J, Ziske C, Goker E. What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?-Results from the lung cancer economics and outcomes research (LUCEOR) study. Lung Cancer. 2013 Oct;82(1):128-35.
Chouaid C, Agulnik J, Goker E, Herder GJ, Lester JF, Vansteenkiste J, Finnern HW, Lungershausen J, Eriksson J, Kim K, Mitchell PL. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013 Aug;8(8):997-1003.
Saly Al-Taei, Josephine Salimu, Jason F. Lester, Seamus Linnane, Madusha Goonewardena, Richard Harrop, Malcolm D. Mason, Zsuzsanna Tabi. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma. Lung Cancer. 2012 Aug;77(2):312-8.
Raphael C, Hudson E, Williams L, Lester JF, Savage PM Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report. J Med Case Reports. 2010 Dec 22;4:413.
Lester JF, Hudson E. Gemcitabine and carboplatin in the treatment of transitional carcinoma of the urothelium. Eur J Cancer Care. 2010 May;19(3):324-8.
Fenwick JD, Nahum AE, Malik ZI, Eswar CV, Hatton MQ, Laurence VM, Lester JF, Landau DB. Escalation and Intensification of Radiotherapy for Stage III Non-small Cell Lung Cancer: Opportunities for Treatment Improvement. Clin Oncol. 2009 May;21(4):343-60.
Din OS, Lester J, Cameron A, Ironside J, Gee A, Falk S, Morgan SA, Worvill J, Hatton MQ. Routine use of continuous, hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer: a five-center experience. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):716-22.
Hudson E, Westmoreland D, Gorman C, Poynton CH, Lester JF, Maughan TS. Severe Prolonged Immunosuppression following Fludarabine and Rituximab Combination Therapy. Chemotherapy. 2008;54:242-244
Hudson E, Rashid M, Carter AC, Lester JF. Basaloid carcinoma of the prostate: a case report and review of the literature. European Journal of Cancer Care. 2008 Sept;17(5):509-11
Hudson E, Kynaston H, Varma M, Carter A, Staffurth J, Barber J, Mason MD, Lester JF. Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies. Clinical Oncology 2008 Jun;20(5):353-7.
E. Hudson, J Powell, S Mukherjee et al. Crosby TD, Brewster AE, Maughan TS, Bailey H, Lester JF. Small cell oesophageal carcinoma: An Institutional Experience and Review of the Literature. British Journal of Cancer. 2007; 96(5):708-1
Lester JF, Macbeth FR. Quality of life assessment in the TAX 326 study.
Lung Cancer. 2007 Feb;55(2):249
Lester JF, Macbeth FR, Toy E, Coles B. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database of systematic reviews. 2006 Oct 18;(4):CD002143.
J.F. Lester, E. Hudson and J.B. Barber. Bladder Preservation in Small Cell Carcinoma of the Urinary Bladder: An Institutional Experience and Review of the Literature. Clinical Oncology. 2006 Oct;18(8):608-11.
Hudson E. Lester JF. Attanoos RL. Linnane SJ. Byrne A. Successful treatment of bronchorrhea with octreotide in a patient with adenocarcinoma of the lung. Journal of Pain & Symptom Management. 2006 Sept;32(3):200-2.
J.F. Lester, E. Hudson, M. Flubacher, F. Macbeth, J. Baker, R. Wade, D. Morrey, L. Hanna, A. Brewster and S.J. Linnane. Small Cell Lung Cancer Treated in Southeast Wales Clinical Oncology. 2006 Jun;18(5):378-82.
Lester JF. Coles B. Macbeth FR. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2005. (2):CD005221,
Lester JF. Macbeth FR. Coles B. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer: A Cochrane Review. International Journal of Radiation, Oncology, Biology, Physics. 2005 Nov 63(3):690-4.
Lester JF. Macbeth FR. Brewster AE. Court JB. Iqbal N. CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer. 2004 Aug;45(2):237-42.
Lester JF. Dojcinov SD. Attanoos RL. O'Brien CJ. Maughan TS. Toy ET. Poynton CH. The clinical impact of expert pathological review on lymphoma management: a regional experience. British Journal of Haematology. 2003 Nov;123(3):463-8.
Book Chapters
Jason Lester and John Wagstaff
Kidney
In: Practical clinical Oncology (2008)
Ed: Louise Hanna
Pub: Cambridge University Press
Saly Al-Taei, Jason F. Lester and Zsuzsanna Tabi (2012). The Role of Immunotherapy in the Treatment of Mesothelioma
In: Mesotheliomas - Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis
Ed: Alexander Zubritsky
Pub: InTech
Jason Francis Lester
Prophylactic Cranial Radiotherapy
In: Advances in Radiation Oncology in lung Cancer (2011)
Ed: Branislav Jeremic
Pub: Springer
Jason Lester, Emma Hudson
Chemotherapy in prostate cancer
In: Challenges in Prostate Cancer, 2nd Edition
Editors: Winsor Bowsher, Adam Carter
Wiley-Blackwell 2006
Jason Lester, Richard Attanoos, Stefan Dojcinov, Ciaran O’Brien.
Clinical impact of pathology errors identified by central pathology review: analysis of over 1000 review cases.
In: The Effective Management of Non-Hodgkin’s lymphoma (2nd edition).
Editors: David Cunningham, Gareth Morgan, Andrew Miles.
Aesculapius Medical Press 2005.
Jason Lester, Fergus Macbeth.
Palliative External Beam Thoracic Radiotherapy.
In: Advances in Radiation Oncology in Lung Cancer (2005)
Editor: Branislav Jeremic
Pub: Springer